<!doctype html><!-- This site was created with Wowchemy. https://www.wowchemy.com --><!-- Last Published: 2023. július 31. --><html lang=hu><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Wowchemy 5.7.0 for Hugo"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=preload as=style href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap"><link rel=stylesheet href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media=print onload='this.media="all"'><link rel=stylesheet href=/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin=anonymous media=print onload='this.media="all"'><link rel=stylesheet href=/css/wowchemy.0f229d4b7ebad1917a9a357cba2effab.css><link rel=stylesheet href=/css/libs/chroma/github-light.min.css title=hl-light media=print onload='this.media="all"'><link rel=stylesheet href=/css/libs/chroma/dracula.min.css title=hl-dark media=print onload='this.media="all"' disabled><script async src="https://www.googletagmanager.com/gtag/js?id=G-YGBRWXZLM1"></script>
<script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}function trackOutboundLink(e,t){gtag("event","click",{event_category:"outbound",event_label:e,transport_type:"beacon",event_callback:function(){t!=="_blank"&&(document.location=e)}}),console.debug("Outbound link clicked: "+e)}function onClickCallback(e){if(e.target.tagName!=="A"||e.target.host===window.location.host)return;trackOutboundLink(e.target,e.target.getAttribute("target"))}gtag("js",new Date),gtag("config","G-YGBRWXZLM1",{}),gtag("set",{cookie_flags:"SameSite=None;Secure"}),document.addEventListener("click",onClickCallback,!1)</script><script>(function(e,t,n,s,o,i,a){e[n]=e[n]||function(){(e[n].q=e[n].q||[]).push(arguments)},i=t.createElement(s),i.async=1,i.src="https://www.clarity.ms/tag/"+o,a=t.getElementsByTagName(s)[0],a.parentNode.insertBefore(i,a)})(window,document,"clarity","script","h7uhlm8mdb")</script><meta name=author content="Ferenci Tamás"><meta name=description content="Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease with risk stratification-based treatment strategy in adults. Although the risk factors have been studied individually in children, effective risk stratification is still lacking. We have tested the prognostic accuracy of pediatric PAH risk factors in our patient group. Patients and methods: Records of 58 PAH patients treated between 1995 and 2019 were reviewed retrospectively. Median age at diagnosis was 4.2 years (range, 0.1-16.1 years), and follow-up was 5.4 years (range, 0.01-24.1 years). Data collected at diagnosis were demographics, World Health Organization functional class, evidence of right ventricular failure, and parameters of echocardiography and cardiac catheterization. Results: Mortality was 29% and 33% reached the composite endpoint. Patients with idiopathic PAH (n = 12) had increased risk of mortality compared with the congenital heart disease-associated PAH group (n = 32) (P = .0024). Neither the initial World Health Organization functional class staging nor the echocardiographic parameters significantly predicted the prognosis. The number of risk factors had no significant prognostic value either. In contrast, patients with higher pulmonary vascular resistance index (PVRI) had significantly increased risk (each 10 Wood units ⋅ m2 increase in PVRI being associated with 49.1% higher hazard, P = .0048). Conclusions: Survival analysis showed that PAH etiology might be an important determinant in pediatric PAH risk stratification. We confirmed that PVRI has predictive value in prognostic assessment. We could not establish the prognostic value of nonweighted single risk factors or their combination to predict pediatric PAH outcome due to the low sample size, but these results indicate that such studies are warranted. © 2021 Elsevier Inc."><link rel=alternate hreflang=hu href=https://www.medstat.hu/publication/mtmt-31918069/><link rel=canonical href=https://www.medstat.hu/publication/mtmt-31918069/><link rel=manifest href=/manifest.webmanifest><link rel=icon type=image/png href=/media/icon_hu577da21a7a63fbc8612c74418210a2c7_11440_32x32_fill_lanczos_center_3.png><link rel=apple-touch-icon type=image/png href=/media/icon_hu577da21a7a63fbc8612c74418210a2c7_11440_180x180_fill_lanczos_center_3.png><meta name=theme-color content="#1565c0"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:image" content="https://www.medstat.hu/media/sharing.png"><meta property="og:site_name" content="Ferenci Tamás honlapja"><meta property="og:url" content="https://www.medstat.hu/publication/mtmt-31918069/"><meta property="og:title" content="Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension | Ferenci Tamás honlapja"><meta property="og:description" content="Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease with risk stratification-based treatment strategy in adults. Although the risk factors have been studied individually in children, effective risk stratification is still lacking. We have tested the prognostic accuracy of pediatric PAH risk factors in our patient group. Patients and methods: Records of 58 PAH patients treated between 1995 and 2019 were reviewed retrospectively. Median age at diagnosis was 4.2 years (range, 0.1-16.1 years), and follow-up was 5.4 years (range, 0.01-24.1 years). Data collected at diagnosis were demographics, World Health Organization functional class, evidence of right ventricular failure, and parameters of echocardiography and cardiac catheterization. Results: Mortality was 29% and 33% reached the composite endpoint. Patients with idiopathic PAH (n = 12) had increased risk of mortality compared with the congenital heart disease-associated PAH group (n = 32) (P = .0024). Neither the initial World Health Organization functional class staging nor the echocardiographic parameters significantly predicted the prognosis. The number of risk factors had no significant prognostic value either. In contrast, patients with higher pulmonary vascular resistance index (PVRI) had significantly increased risk (each 10 Wood units ⋅ m2 increase in PVRI being associated with 49.1% higher hazard, P = .0048). Conclusions: Survival analysis showed that PAH etiology might be an important determinant in pediatric PAH risk stratification. We confirmed that PVRI has predictive value in prognostic assessment. We could not establish the prognostic value of nonweighted single risk factors or their combination to predict pediatric PAH outcome due to the low sample size, but these results indicate that such studies are warranted. © 2021 Elsevier Inc."><meta property="og:image" content="https://www.medstat.hu/media/sharing.png"><meta property="og:locale" content="hu"><meta property="article:published_time" content="2023-04-10T18:20:18+00:00"><meta property="article:modified_time" content="2023-04-10T20:20:18+02:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://www.medstat.hu/publication/mtmt-31918069/"},"headline":"Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension","datePublished":"2023-04-10T18:20:18Z","dateModified":"2023-04-10T20:20:18+02:00","author":{"@type":"Person","name":"László Ablonczy"},"publisher":{"@type":"Organization","name":"Ferenci Tamás honlapja","logo":{"@type":"ImageObject","url":"https://www.medstat.hu/media/icon_hu577da21a7a63fbc8612c74418210a2c7_11440_192x192_fill_lanczos_center_3.png"}},"description":"Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease with risk stratification-based treatment strategy in adults. Although the risk factors have been studied individually in children, effective risk stratification is still lacking. We have tested the prognostic accuracy of pediatric PAH risk factors in our patient group. Patients and methods: Records of 58 PAH patients treated between 1995 and 2019 were reviewed retrospectively. Median age at diagnosis was 4.2 years (range, 0.1-16.1 years), and follow-up was 5.4 years (range, 0.01-24.1 years). Data collected at diagnosis were demographics, World Health Organization functional class, evidence of right ventricular failure, and parameters of echocardiography and cardiac catheterization. Results: Mortality was 29% and 33% reached the composite endpoint. Patients with idiopathic PAH (n = 12) had increased risk of mortality compared with the congenital heart disease-associated PAH group (n = 32) (P = .0024). Neither the initial World Health Organization functional class staging nor the echocardiographic parameters significantly predicted the prognosis. The number of risk factors had no significant prognostic value either. In contrast, patients with higher pulmonary vascular resistance index (PVRI) had significantly increased risk (each 10 Wood units ⋅ m2 increase in PVRI being associated with 49.1% higher hazard, P = .0048). Conclusions: Survival analysis showed that PAH etiology might be an important determinant in pediatric PAH risk stratification. We confirmed that PVRI has predictive value in prognostic assessment. We could not establish the prognostic value of nonweighted single risk factors or their combination to predict pediatric PAH outcome due to the low sample size, but these results indicate that such studies are warranted. © 2021 Elsevier Inc."}</script><title>Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension | Ferenci Tamás honlapja</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents class=page-wrapper data-wc-page-id=3e07cc3b947e9a1eebc4cb121477f663><script src=/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js></script><aside class=search-modal id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Keresés</h1></div><div class="col-6 col-search-close"><a class=js-search href=# aria-label=Close><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Keresés... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search class=form-control aria-label=Keresés...></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><div class="page-header header--fixed"><header><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container-xl><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/>Ferenci Tamás honlapja</a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar-content aria-expanded=false aria-label=Navigáció>
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/>Ferenci Tamás honlapja</a></div><div class="navbar-collapse main-menu-item collapse justify-content-start" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/#about><span>Rólam</span></a></li><li class=nav-item><a class=nav-link href=/#oktatas><span>Oktatás</span></a></li><li class=nav-item><a class=nav-link href=/#projektek><span>Projektjeim</span></a></li><li class=nav-item><a class=nav-link href=/#esszek><span>Esszéim</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Cikkek</span></a></li><li class=nav-item><a class=nav-link href=/#contact><span>Kapcsolat</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=# aria-label=Keresés><i class="fas fa-search" aria-hidden=true></i></a></li><li class="nav-item dropdown theme-dropdown"><a href=# class=nav-link data-toggle=dropdown aria-haspopup=true aria-label="Display preferences"><i class="fas fa-moon" aria-hidden=true></i></a><div class=dropdown-menu><a href=# class="dropdown-item js-set-theme-light"><span>Light</span></a>
<a href=# class="dropdown-item js-set-theme-dark"><span>Dark</span></a>
<a href=# class="dropdown-item js-set-theme-auto"><span>Automatic</span></a></div></li></ul></div></nav></header></div><div class=page-body><div class=pub><div class="article-container pt-3"><h1>Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension</h1><div class=article-metadata><div><span>László Ablonczy</span>, <span>Tamás Ferenci</span>, <span>O. Somoskövi</span>, <span>R. Osváth</span>, <span>György Reusz</span>, <span>Éva PhD Kis</span></div><span class=article-date>január, 2021</span></div><div class="btn-links mb-3"><a href=# class="btn btn-outline-primary btn-page-header js-cite-modal" data-filename=/publication/mtmt-31918069/cite.bib>Idézet</a>
<a class="btn btn-outline-primary btn-page-header" href=https://doi.org/10.1016/j.transproceed.2021.01.047 target=_blank rel=noopener>DOI</a>
<a class="btn btn-outline-primary btn-page-header" href=https://m2.mtmt.hu/api/publication/31918069 target=_blank rel=noopener>URL</a></div></div><div class=article-container><h3>Kivonat</h3><p class=pub-abstract>Background: Pulmonary arterial hypertension (PAH) is a life-threatening disease with risk stratification-based treatment strategy in adults. Although the risk factors have been studied individually in children, effective risk stratification is still lacking. We have tested the prognostic accuracy of pediatric PAH risk factors in our patient group. Patients and methods: Records of 58 PAH patients treated between 1995 and 2019 were reviewed retrospectively. Median age at diagnosis was 4.2 years (range, 0.1-16.1 years), and follow-up was 5.4 years (range, 0.01-24.1 years). Data collected at diagnosis were demographics, World Health Organization functional class, evidence of right ventricular failure, and parameters of echocardiography and cardiac catheterization. Results: Mortality was 29% and 33% reached the composite endpoint. Patients with idiopathic PAH (n = 12) had increased risk of mortality compared with the congenital heart disease-associated PAH group (n = 32) (P = .0024). Neither the initial World Health Organization functional class staging nor the echocardiographic parameters significantly predicted the prognosis. The number of risk factors had no significant prognostic value either. In contrast, patients with higher pulmonary vascular resistance index (PVRI) had significantly increased risk (each 10 Wood units ⋅ m2 increase in PVRI being associated with 49.1% higher hazard, P = .0048). Conclusions: Survival analysis showed that PAH etiology might be an important determinant in pediatric PAH risk stratification. We confirmed that PVRI has predictive value in prognostic assessment. We could not establish the prognostic value of nonweighted single risk factors or their combination to predict pediatric PAH outcome due to the low sample size, but these results indicate that such studies are warranted. © 2021 Elsevier Inc.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Típus</div><div class="col-12 col-md-9"><a href=/publication/#2>Journal article</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publikáció</div><div class="col-12 col-md-9"><em>TRANSPLANTATION PROCEEDINGS</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=share-box><ul class=share><li><a href="mailto:?subject=Prognostic%20Value%20of%20Early%20Risk%20Stratification%20in%20Pediatric%20Pulmonary%20Arterial%20Hypertension&amp;body=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31918069%2F" target=_blank rel=noopener class=share-btn-email aria-label=envelope><i class="fas fa-envelope"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31918069%2F&amp;t=Prognostic+Value+of+Early+Risk+Stratification+in+Pediatric+Pulmonary+Arterial+Hypertension" target=_blank rel=noopener class=share-btn-facebook aria-label=facebook><i class="fab fa-facebook"></i></a></li><li><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31918069%2F&amp;text=Prognostic+Value+of+Early+Risk+Stratification+in+Pediatric+Pulmonary+Arterial+Hypertension" target=_blank rel=noopener class=share-btn-twitter aria-label=twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31918069%2F&amp;title=Prognostic+Value+of+Early+Risk+Stratification+in+Pediatric+Pulmonary+Arterial+Hypertension" target=_blank rel=noopener class=share-btn-linkedin aria-label=linkedin-in><i class="fab fa-linkedin-in"></i></a></li><li><a href="https://reddit.com/submit?url=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31918069%2F&amp;title=Prognostic+Value+of+Early+Risk+Stratification+in+Pediatric+Pulmonary+Arterial+Hypertension" target=_blank rel=noopener class=share-btn-reddit aria-label=reddit-alien><i class="fab fa-reddit-alien"></i></a></li></ul></div></div></div></div><div class=page-footer><div class=container><footer class=site-footer><p class="powered-by copyright-license-text">© 2023 Ferenci Tamás. This work is licensed under <a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank>CC BY NC ND 4.0</a></p><p class="powered-by footer-license-icons"><a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank aria-label="Creative Commons"><i class="fab fa-creative-commons fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-by fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nc fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nd fa-2x" aria-hidden=true></i></a></p><p class=powered-by>Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target=_blank rel=noopener>Wowchemy</a> — the free, <a href=https://github.com/wowchemy/wowchemy-hugo-themes target=_blank rel=noopener>open source</a> website builder that empowers creators.</p></footer></div></div><script src=/js/vendor-bundle.min.32ee83730ed883becad04bc5170512cc.js></script>
<script id=search-hit-fuse-template type=text/x-template>
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script><script src=https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin=anonymous></script>
<script id=page-data type=application/json>{"use_headroom":true}</script><script src=/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js type=module></script>
<script src=/hu/js/wowchemy.min.1d2d59f81f85a9534f4e719314fc9a11.js></script><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Idézet</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Másolat</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Letöltés</a><div id=modal-error></div></div></div></div></div><script src=/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js type=module></script>
<script type=text/javascript>var sc_project=8274576,sc_invisible=1,sc_security="b688857d"</script><script type=text/javascript src=https://www.statcounter.com/counter/counter.js async></script><noscript><div class=statcounter><a title="ingyenes
webstatisztika" href=https://www.statcounter.hu/ target=_blank><img class=statcounter src=https://c.statcounter.com/8274576/0/b688857d/1/ alt="ingyenes webstatisztika" referrerpolicy=no-referrer-when-downgrade></a></div></noscript></body></html>